Insights into Imaging (Aug 2021)

Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging (EUSOBI)

  • Simone Schiaffino,
  • Katja Pinker,
  • Veronica Magni,
  • Andrea Cozzi,
  • Alexandra Athanasiou,
  • Pascal A. T. Baltzer,
  • Julia Camps Herrero,
  • Paola Clauser,
  • Eva M. Fallenberg,
  • Gábor Forrai,
  • Michael H. Fuchsjäger,
  • Thomas H. Helbich,
  • Fleur Kilburn-Toppin,
  • Christiane K. Kuhl,
  • Mihai Lesaru,
  • Ritse M. Mann,
  • Pietro Panizza,
  • Federica Pediconi,
  • Ruud M. Pijnappel,
  • Tamar Sella,
  • Isabelle Thomassin-Naggara,
  • Sophia Zackrisson,
  • Fiona J. Gilbert,
  • Francesco Sardanelli

DOI
https://doi.org/10.1186/s13244-021-01062-x
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Unilateral axillary lymphadenopathy is a frequent mild side effect of COVID-19 vaccination. European Society of Breast Imaging (EUSOBI) proposes ten recommendations to standardise its management and reduce unnecessary additional imaging and invasive procedures: (1) in patients with previous history of breast cancer, vaccination should be performed in the contralateral arm or in the thigh; (2) collect vaccination data for all patients referred to breast imaging services, including patients undergoing breast cancer staging and follow-up imaging examinations; (3) perform breast imaging examinations preferentially before vaccination or at least 12 weeks after the last vaccine dose; (4) in patients with newly diagnosed breast cancer, apply standard imaging protocols regardless of vaccination status; (5) in any case of symptomatic or imaging-detected axillary lymphadenopathy before vaccination or at least 12 weeks after, examine with appropriate imaging the contralateral axilla and both breasts to exclude malignancy; (6) in case of axillary lymphadenopathy contralateral to the vaccination side, perform standard work-up; (7) in patients without breast cancer history and no suspicious breast imaging findings, lymphadenopathy only ipsilateral to the vaccination side within 12 weeks after vaccination can be considered benign or probably-benign, depending on clinical context; (8) in patients without breast cancer history, post-vaccination lymphadenopathy coupled with suspicious breast finding requires standard work-up, including biopsy when appropriate; (9) in patients with breast cancer history, interpret and manage post-vaccination lymphadenopathy considering the timeframe from vaccination and overall nodal metastatic risk; (10) complex or unclear cases should be managed by the multidisciplinary team.

Keywords